REG - Oncimmune Hldgs PLC - Two further ImmunoINSIGHTS contracts signed

Oncimmune HoldingsAnnouncement

08/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220408:nRSH7243Ha&default-theme=true

RNS Number : 7243H  Oncimmune Holdings PLC  08 April 2022

8 April 2022

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Two further ImmunoINSIGHTS contracts signed

 

Projects with two US-based clinical-stage biopharmaceutical companies
demonstrates the impact of the Company's new Commercial team

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces the signing of two new ImmunoINSIGHTS commercial
contracts.

 

The first contract is with an US-based clinical-stage biopharmaceutical
company which is developing first-in-class cellular immunotherapies for cancer
patients utilizing off-the-shelf natural killer ("NK") cell and CAR-NK cell
products. Under this contract, Oncimmune will utilize its specific
high-throughput proprietary biomarker discovery platform, SeroTag(TM), to
identify autoantibodies that can be predictive of patient clinical response,
and potential resistance to engineered cellular therapies in hematological and
solid tumor oncology indications.

 

This new contract demonstrates the significant potential that the Company's
ImmunoINSIGHTS technology platform could have in the engineered cellular
therapy place.

 

The second contract signed is with a US-based clinical-stage biopharmaceutical
company focused on developing a proprietary technology which harnesses the
power of the immune system, to combat cancer by leveraging their proprietary
technology to discover, develop and commercialize transformative oncology
treatments. This project will profile the autoantibodies in patients treated
with a virus-like particle which stimulates anti-tumor T cells. By profiling
patients longitudinally, the aim of the project is to demonstrate how the
immune system is affected by this therapy.

 

Dr Adam M Hill, CEO of Oncimmune said: "We are pleased to announce a further
two contracts with our ImmunoINSIGHTS platform which demonstrates the progress
that our Commercial team are making from our new US office in Boston. We are
particularly excited by the signing of our first contract within the allogenic
and CAR-NK market segment which we believe could open up a new opportunity for
our services in the engineered cellular therapy space. Unlocking the utility
of the ImmunoINSIGHTS platform in these cutting-edge therapies promises to
substantially improve clinical outcomes for cancer patients."

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research center in Dortmund, Germany. The business platform enables
life science organizations to optimize drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programs, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

What is SeroTag(TM)?

 

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our
ImmunoINSIGHTS services to discover and validate novel biomarkers can help
stratify patients in multiple cancer indications and with different autoimmune
diseases.

 

This high-throughput, multiplex technology is based on one of the largest,
in-house protein libraries, as well as a unique, ever-growing repository of
disease data for indications including, but not limited to, autoimmune
diseases and cancer. As a result, SeroTag is helping to address and monitor a
number of challenges currently hindering the successful development and
broader application of both cancer immunotherapies and treatments for
autoimmune diseases.

 

The platform is being applied to discover and validate biomarkers and develop
precision diagnostic tools from minimally invasive liquid biopsies. SeroTag
analyzes autoantibodies-some of the most stable analytes-and is used most
frequently for the identification of IgG isoforms, in addition to IgM and IgA,
from just a few drops of serum.

 

The SeroTag platform acts as the primary discovery engine that feeds into the
creation of Oncimmune's NavigAID(TM) disease-specific stratification panels.
These precision medicine tools which are enabling patient and disease
stratification and support therapeutic development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBKOBPKBKBKQK